WO1997029113A3 - Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung - Google Patents

Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung Download PDF

Info

Publication number
WO1997029113A3
WO1997029113A3 PCT/EP1997/000321 EP9700321W WO9729113A3 WO 1997029113 A3 WO1997029113 A3 WO 1997029113A3 EP 9700321 W EP9700321 W EP 9700321W WO 9729113 A3 WO9729113 A3 WO 9729113A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
purified nucleic
preparing purified
protein
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/000321
Other languages
English (en)
French (fr)
Other versions
WO1997029113A2 (de
Inventor
Wolfgang Kuhne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1997029113(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP97901080.8A priority Critical patent/EP0880536B2/de
Priority to US09/117,537 priority patent/US6750333B1/en
Priority to ES97901080.8T priority patent/ES2195112T5/es
Priority to AT97901080T priority patent/ATE238321T1/de
Priority to DE59709915T priority patent/DE59709915D1/de
Priority to AU14449/97A priority patent/AU1444997A/en
Priority to DK97901080.8T priority patent/DK0880536T4/en
Priority to JP52809697A priority patent/JP3442788B2/ja
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to CA002245576A priority patent/CA2245576C/en
Publication of WO1997029113A2 publication Critical patent/WO1997029113A2/de
Publication of WO1997029113A3 publication Critical patent/WO1997029113A3/de
Anticipated expiration legal-status Critical
Priority to US11/389,167 priority patent/US20060165660A1/en
Priority to US12/627,449 priority patent/US20100074946A1/en
Priority to US13/197,225 priority patent/US20110293708A1/en
Priority to US13/545,427 priority patent/US20130004562A1/en
Priority to US13/938,398 priority patent/US20130315985A1/en
Priority to US14/277,415 priority patent/US9421279B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Eine Nukleinsäurepräparation mit einem Gehalt von weniger als 1 % Protein, vorzugsweise weniger als 0,1 % Protein, frei von Ethidiumbromid, Phenol, Cäsiumchlorid und Detergentien auf Basis von Octylphenolpoly(ethylenglycolether)n sowie mit einem Gehalt von weniger als 1 EU/mg DNA an Endotoxinen ist als Arzneimittel insbesondere in der Gentherapie geeignet.
PCT/EP1997/000321 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung Ceased WO1997029113A2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA002245576A CA2245576C (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
US09/117,537 US6750333B1 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
ES97901080.8T ES2195112T5 (es) 1996-02-06 1997-01-24 Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo
AT97901080T ATE238321T1 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung
DE59709915T DE59709915D1 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung
EP97901080.8A EP0880536B2 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung
AU14449/97A AU1444997A (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
DK97901080.8T DK0880536T4 (en) 1996-02-06 1997-01-24 A process for the preparation of purified nucleic acid and the use thereof
JP52809697A JP3442788B2 (ja) 1996-02-06 1997-01-24 精製核酸の製法及びその使用
US11/389,167 US20060165660A1 (en) 1996-02-06 2006-03-27 Process for preparing purified nucleic acid and the use thereof
US12/627,449 US20100074946A1 (en) 1996-02-06 2009-11-30 Process for preparing purified nucleic acid and the use thereof
US13/197,225 US20110293708A1 (en) 1996-02-06 2011-08-03 Process for preparing purified nucleic acid and the use thereof
US13/545,427 US20130004562A1 (en) 1996-02-06 2012-07-10 Process for preparing purified nucleic acid and the use thereof
US13/938,398 US20130315985A1 (en) 1996-02-06 2013-07-10 Process for preparing purified nucleic acid and the use thereof
US14/277,415 US9421279B2 (en) 1996-02-06 2014-05-14 Process for preparing purified nucleic acid and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96101628 1996-02-06
EP96101628.4 1996-02-06

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/117,537 A-371-Of-International US6750333B1 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
US09117537 A-371-Of-International 1997-01-24
US10/771,371 Division US20040209835A1 (en) 1996-02-06 2004-02-05 Process for preparing purified nucleic acid and the use thereof

Publications (2)

Publication Number Publication Date
WO1997029113A2 WO1997029113A2 (de) 1997-08-14
WO1997029113A3 true WO1997029113A3 (de) 1997-10-02

Family

ID=8222465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000321 Ceased WO1997029113A2 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung

Country Status (12)

Country Link
US (8) US6750333B1 (de)
EP (1) EP0880536B2 (de)
JP (1) JP3442788B2 (de)
KR (1) KR100318808B1 (de)
CN (1) CN1121408C (de)
AT (1) ATE238321T1 (de)
AU (1) AU1444997A (de)
CA (1) CA2245576C (de)
DE (1) DE59709915D1 (de)
DK (1) DK0880536T4 (de)
ES (1) ES2195112T5 (de)
WO (1) WO1997029113A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746412B1 (fr) 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
DE19859703B4 (de) 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
DE19903507A1 (de) 1999-01-29 2000-08-10 Roche Diagnostics Gmbh Verfahren zur Herstellung endotoxinfreier oder an Endotoxin abgereicherter Nukleinsäuren und deren Verwendung
DE50008101D1 (de) * 2000-02-16 2004-11-11 Macherey Nagel Gmbh & Co Hg Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
KR100356738B1 (ko) * 2000-09-07 2002-10-18 주식회사 삼양제넥스 염기성 단백질로부터 엔도톡신을 제거하는 방법
GB0028361D0 (en) * 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
GB0217963D0 (en) * 2002-08-02 2002-09-11 Cyclops Genome Sciences Ltd Purification of nucleic acids
DE10238630A1 (de) * 2002-08-19 2004-03-04 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Isolierung biologischer Makromoleküle sowie Vorrichtung zur Durchführung dieses Verfahrens
JP2005538717A (ja) * 2002-09-13 2005-12-22 ヴァレンティス，インコーポレイテッド 核酸のプレパラティブスケールの精製のための装置および方法
ATE547442T1 (de) 2004-04-02 2012-03-15 Nexttec Gmbh Verfahren zur herstellung eines verbundsorptionsmaterials für die chromatographische trennung von biopolymeren
JP5820564B2 (ja) * 2006-05-24 2015-11-24 スカラブ ゲノミクス， エルエルシー プラスミドｄｎａ調製物およびそれらの作製方法
US8093364B2 (en) * 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
US8969068B2 (en) * 2008-04-30 2015-03-03 Gradalis, Inc. Processes for the preparation of highly pure plasmid compositions by enzymatic digestion of colanic acid
HUE031720T2 (en) 2009-05-26 2017-07-28 Eurogentec Sa Method and means for the preparation and / or purification of polynucleotides and products thereof
AU2010292897B2 (en) * 2009-08-06 2016-01-07 Genentech, Inc. Method to improve virus removal in protein purification
CN108148831A (zh) * 2018-01-15 2018-06-12 南京驯鹿医疗技术有限公司 一种无内毒素质粒大量制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268946A2 (de) * 1986-11-22 1988-06-01 DIAGEN Institut für molekularbiologische Diagnostik GmbH Verfahren zur Isolierung von langkettiger Nukleinsäure
WO1995021179A1 (de) * 1994-02-07 1995-08-10 Qiagen Gmbh Verfahren zur abreicherung oder entfernung von endotoxinen
WO1995021250A2 (en) * 1994-02-01 1995-08-10 Vical Incorporated Production of pharmaceutical-grade plasmid dna

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135792A (ja) 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc 核酸の分離・精製方法
US5990301A (en) * 1994-02-07 1999-11-23 Qiagen Gmbh Process for the separation and purification of nucleic acids from biological sources
AU708798B2 (en) 1994-07-15 1999-08-12 Merck & Co., Inc. A method for large scale plasmid purification
US5576196A (en) 1995-01-13 1996-11-19 Vical Incorporated Process for reducing RNA concentration in a mixture of biological material using diatomaceous earth
US6214586B1 (en) * 1997-12-08 2001-04-10 Genzyme Corporation Method for purifying plasmid DNA and plasmid DNA substantially free of genomic DNA
US6759394B2 (en) * 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268946A2 (de) * 1986-11-22 1988-06-01 DIAGEN Institut für molekularbiologische Diagnostik GmbH Verfahren zur Isolierung von langkettiger Nukleinsäure
WO1995021250A2 (en) * 1994-02-01 1995-08-10 Vical Incorporated Production of pharmaceutical-grade plasmid dna
WO1995021179A1 (de) * 1994-02-07 1995-08-10 Qiagen Gmbh Verfahren zur abreicherung oder entfernung von endotoxinen
WO1995021177A1 (de) * 1994-02-07 1995-08-10 Qiagen Gmbh Verfahren zur herstellung endotoxinfreier oder an endotoxin abgereicherter nucleinsäuren und/oder oligonucleotide für die gentherapie

Also Published As

Publication number Publication date
US20040209835A1 (en) 2004-10-21
US20060165660A1 (en) 2006-07-27
EP0880536B1 (de) 2003-04-23
KR19990082308A (ko) 1999-11-25
DK0880536T3 (da) 2003-08-11
US20110293708A1 (en) 2011-12-01
WO1997029113A2 (de) 1997-08-14
CN1121408C (zh) 2003-09-17
EP0880536B2 (de) 2015-08-05
CA2245576C (en) 2004-03-23
US20130315985A1 (en) 2013-11-28
JP3442788B2 (ja) 2003-09-02
DE59709915D1 (de) 2003-05-28
DK0880536T4 (en) 2015-09-07
CN1210541A (zh) 1999-03-10
US20130004562A1 (en) 2013-01-03
AU1444997A (en) 1997-08-28
CA2245576A1 (en) 1997-08-14
KR100318808B1 (ko) 2004-05-20
US20100074946A1 (en) 2010-03-25
ATE238321T1 (de) 2003-05-15
ES2195112T3 (es) 2003-12-01
US20140287026A1 (en) 2014-09-25
US9421279B2 (en) 2016-08-23
JPH11509554A (ja) 1999-08-24
US6750333B1 (en) 2004-06-15
EP0880536A2 (de) 1998-12-02
ES2195112T5 (es) 2015-10-15

Similar Documents

Publication Publication Date Title
AU1444997A (en) Process for preparing purified nucleic acid and the use thereof
Sato et al. A thermostable sequence-specific endonuclease from Thermus aquaticus.
Gullberg et al. The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity
EP0092574A4 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
AU2284697A (en) Fusogenic liposomes
CA2182388A1 (en) Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
AU1458395A (en) Composition containing nucleic acids, preparation and uses
IE960853L (en) Vascular anticoagulant proteins
AU7247891A (en) Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
GR3031789T3 (en) Novel colon- or ileum-specific steroid derivatives.
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
KR890701731A (ko) 칼리크레인의 제조방법
DE3271862D1 (en) Chemokinesins and chemotaxins of leukocytes and inflamed tissues: natural mediator proteins for reversible promotion of random and directional locomotion (chemokinesis and chemotaxis) for accumulation of specific leukocyte types, process of their biotechnical preparation and pharmaceutical compositions
NZ296561A (en) Adjuvant for attachment to molecule to improve activity, complex, preparation, nucleotide sequence and vaccine
AU7440087A (en) Process for isolating and purifying p. falciparum cs protein vaccine expressed in recombinant e. coli
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
MX9806041A (es) Proteina purificada sr-p70.
Drahovsky et al. Distribution pattern and enzymic hypermethylation of inverted repetitive DNA sequences in P815 mastocytoma cells
Isaacson et al. Assays of antimicrobial substances.
EP1246678A4 (de) Träger zur trennung von physiologischen flüssigkeiten mit verbesserter interner migration von therapeutischen substanzen
Thang et al. Interaction of interferon with tRNA
DE69730967D1 (en) Human dnase ii
Ryskov et al. The localization of polyadenylic sequence at the 5′‐end of light nuclear dRNA
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192102.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1997901080

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 528096

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09117537

Country of ref document: US

Ref document number: PA/A/1998/006279

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2245576

Country of ref document: CA

Ref document number: 2245576

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980706038

Country of ref document: KR

NENP Non-entry into the national phase

Ref document number: 97528096

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1997901080

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980706038

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019980706038

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997901080

Country of ref document: EP